Compare KeyCorp (KEY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Summit Therapeutics Inc — how do they compare? KeyCorp trades at $22.7 (market cap $24.32B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: KeyCorp is far larger — about 2× Summit Therapeutics Inc's market cap, and KeyCorp pays a 3.61% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KEY | SMMT | |
|---|---|---|
Market Cap | $24.32B | $12.06B |
Sector | Financials | Health |
52-Week High | $23.99 | $26.98 |
52-Week Low | $16.78 | $12.55 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $22.94, up 1.15% today, with a bullish analyst consensus and consistent earnings beats. The stock shows a P/E of 13.27 and net income margin of 26.72%, supported by strong Q2 2026 results. Recent acquisition of Clearwater UK expands its investment banking footprint, while technical indicators signal a bearish trend despite neutral oscillators.
Outlook remains positive with a $29.41 price target, driven by net interest income growth and fee-based expansion. Risks include economic uncertainty impacting loan demand and competitive pressures. The dividend yield of approximately 3.6% adds income appeal, but investors should monitor margin sustainability and macroeconomic headwinds.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
